Immunomedics Inc (NASDAQ:IMMU) shares traded 0% up during most recent session to reach at the closing price of $7.71. The stock exchanged hands 1.25 Million shares versus average trading capacity of 2.99 Million shares, yielding a market cap of $806.47 Million. Wall Street analysts covering the stock are projecting that the stock will reach $11.83 within the next 52-weeks. The mean target projections are based on 3 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Immunomedics Inc (NASDAQ:IMMU) high price target of $15 and with a conservative view have low price target of $9.
Cowen & Co. “Initiates Coverage On” Immunomedics Inc (NASDAQ:IMMU) in a research note issued to investors on 5/26/17 to Outperform with price target of $15.
Additionally on 10/06/16 Jefferies “Assumes” Immunomedics Inc (NASDAQ:IMMU) to Buy setting price target at $ and on 6/21/16 Wells Fargo “Downgrades” the stock to Market Perform. Furthermore on 5/06/16 Jefferies “Upgrades” the stock to Buy at $5.
On the other hand the company has Relative Strength Index (RSI 14) of 53.63 along with Average True Range (ATR 14) of 0.45, Consequently Immunomedics Inc (NASDAQ:IMMU)’s weekly and monthly volatility is 7.26%, 5.64% respectively. The company’s beta value is at 1.73.
In terms of Buy, Sell or Hold recommendations, Immunomedics Inc (NASDAQ:IMMU) has analysts’ mean recommendation of 1.3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Immunomedics Inc (NASDAQ:IMMU)’s minimum EPS for the current quarter is at $-0.16 and can go high up to $-0.1. The consensus mean EPS for the current quarter is at $-0.12 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.17 earnings per share for the same quarter during last year.
Previously Immunomedics Inc (NASDAQ:IMMU) reported $-0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.13 by $-0.42. The company posted an earnings surprise of -323.1%.
Immunomedics Inc (NASDAQ:IMMU)’s revenue estimates for the current quarter are $2.33 Million according to 3 number of analysts, for the current quarter the company has high revenue estimates of $5.5 Million in contradiction of low revenue estimates of $600 Million. For the current year the company’s revenue estimates are $4.77 Million compared to low analyst estimates of $3 Million and high estimates of $8 Million according to 3 number of analysts.
Currently Immunomedics Inc (NASDAQ:IMMU)’s shares owned by insiders are 6.84%, whereas shares owned by institutional owners are 66.3%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 20.73%.
Immunomedics Inc (NASDAQ:IMMU) 52-week high price stands at $8.44 and low price stands at $1.95, its price distance from 52-week high is -8.65% while its distance from 52-week low price is 295.38%. The stock hit its 52-week high on 06/12/17, and 52-week low on 06/27/16.
Immunomedics Inc (NASDAQ:IMMU)’s trailing twelve month revenues are $3.4 Million, whereas its price to sales ratio for the same period is 237.2. Its book value per share for the most recent quarter is $-1.22 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.44, however its price to cash per share ratio for the same period is 17.53. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.